France· FR:63017696
MITOMYCINE SUBSTIPHARM 20 mg, poudre pour solution injectable/perfusion ou voie intravésicale
A medicinal product containing mitomycine c, registered in France by SUBSTIPHARM.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MITOMYCINE C
- Manufacturer
- SUBSTIPHARM
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009301865101 flacon en verre jaune(brun) de 50 ml avec 1 filtre stérile à usage unique poly(fluorure de vinylidène) (PVDF)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mitomycine c in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsMitomycine Accord 20 mg, poeder voor oplossing voor injectie / infusie of intravesicaal gebruikAccord Healthcare B.V.
- United StatesMitomycinArchis Pharma LLC
- BelgiumMitomycin Accord Healthcare 10 mgAccord Healthcare
- GermanyMitemSubstipharm
- United KingdomMitocin 20mg powder and solvent for intravesical solution vialsVygoris Ltd
- CzechiaMITOMYCIN ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- SpainMITOMICINA ACCORD 10 MG POLVO PARA SOLUCION INTRAVESICAL Y PARA SOLUCION INYECTABLE EFGAccord Healthcare S.L.U.
- FinlandMitomycin AccordAccord Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Mitomycin Medac
- Belgium · Mitomycin Accord Healthcare, Mitomycin Medac
- Bulgaria · Митомицин Акорд
- Cyprus · Mitomycin Accord, Mitomycine Substipharm
- Czechia · Mitomycin Accord, Mitomycin Medac
- Germany · Mitem, Mito-Apogepha
- Denmark · Mitomycin Medac
- Estonia · Mitomycin Accord, Mitomycin Medac
- Spain · Mitomicina Accord, Mitomicina Aurovitas
- Finland · Mitomycin Accord, Mitomycin Medac
- United Kingdom (Northern Ireland) · Mitocin, Mitomycin Accord Healthcare
- Ireland · Mitomycin Medac
- Iceland · Mitomycin Medac
- Italy · Mitomicina Accord, Mitomicina Medac
- Lithuania · Mitomycin Medac
- Latvia · Mitomycin Medac
- Malta · Mitomycine Substipharm
- Netherlands · Mitomycine Accord, Mitomycine Medac
- Norway · Mitomycin Medac, Mitomycin Substipharm
- Poland · Mitomycin Accord
- Portugal · Mitomicina Accord, Mitomicina Accord Healthcare
- Romania · Mitomicină Accord
- Sweden · Mitomycin Medac, Mitomycin Substipharm
- Slovenia · Mitomicin Accord, Mitomicin Medac
- Slovakia · Mitomycin Accord, Mitomycin Medac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/93c5819d-c2ae-41d5-93c4-8e8dee15fb90 GET /v1/drugs/93c5819d-c2ae-41d5-93c4-8e8dee15fb90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63017696",
"date_amm": "2019-08-01",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "MITOMYCINE C",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution injectable pour perfusion ou",
"voies_administration": "intraartérielle;intraséreuse;intraveineuse;intravésicale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mitomycine c.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.